Skip to main content
Journal cover image

Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database.

Publication ,  Journal Article
Schwann, TA; Vekstein, AM; Engelman, DT; Thibault, D; Chikwe, J; Engoren, M; Gaudino, M; Vemulapalli, S; Thourani, VH; Ailawadi, G; Rousou, A ...
Published in: Ann Thorac Surg
November 2023

BACKGROUND: Anticoagulation after bioprosthetic mitral valve (MV) replacement (BMVR) and repair (MVrep) is controversial. We explore outcomes among BMVR and MVrep patients in The Society of Thoracic Surgeons Adult Cardiac Surgery Database based on discharge anticoagulation status. METHODS: BMVR and MVrep patients aged ≥65 years in The Society of Thoracic Surgeons Adult Cardiac Surgery Database were linked to the Centers for Medicare and Medicaid Services claims database. Long-term mortality, ischemic stroke, bleeding, and a composite of the primary end points were compared as a function of anticoagulation. Hazard ratios (HRs) were calculated using multivariable Cox regression. RESULTS: A total of 26,199 BMVR and MVrep patients were linked to the Centers for Medicare and Medicaid Services database; of these, 44%, 4%, and 52% were discharged on warfarin, non-vitamin K-dependent anticoagulant (NOAC), and no anticoagulation (no-AC; reference), respectively. Warfarin was associated with increased bleeding in the overall study cohort (HR, 1.38; 95% CI 1.26-1.52) and in the BMVR (HR, 1.32; 95% CI, 1.13-1.55) and MVrep subcohorts (HR, 1.42; 95% CI, 1.26-1.60). Warfarin was associated with decreased mortality only among BMVR patients (HR, 0.87; 95% CI, 0.79-0.96). Stroke and the composite outcome did not differ across cohorts with warfarin. NOAC use was associated with increased mortality (HR, 1.33; 95% CI 1.11-1.59), bleeding (HR, 1.37; 95% CI, 1.07-1.74), and the composite outcome (HR, 1.26; 95% CI, 1.08-1.47). CONCLUSIONS: Anticoagulation was used in fewer than half of mitral valve operations. In MVrep patients, warfarin was associated with increased bleeding and was not protective against stroke or mortality. In BMVR patients, warfarin was associated with a modest survival benefit, increased bleeding, and equivalent stroke risk. NOAC was associated with increased adverse outcomes.

Duke Scholars

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

November 2023

Volume

116

Issue

5

Start / End Page

944 / 953

Location

Netherlands

Related Subject Headings

  • Warfarin
  • United States
  • Treatment Outcome
  • Time Factors
  • Thoracic Surgery
  • Societies, Medical
  • Retrospective Studies
  • Respiratory System
  • Postoperative Complications
  • Mitral Valve
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schwann, T. A., Vekstein, A. M., Engelman, D. T., Thibault, D., Chikwe, J., Engoren, M., … Habib, R. H. (2023). Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database. Ann Thorac Surg, 116(5), 944–953. https://doi.org/10.1016/j.athoracsur.2023.05.025
Schwann, Thomas A., Andrew M. Vekstein, Daniel T. Engelman, Dylan Thibault, Joanna Chikwe, Milo Engoren, Mario Gaudino, et al. “Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database.Ann Thorac Surg 116, no. 5 (November 2023): 944–53. https://doi.org/10.1016/j.athoracsur.2023.05.025.
Schwann TA, Vekstein AM, Engelman DT, Thibault D, Chikwe J, Engoren M, et al. Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2023 Nov;116(5):944–53.
Schwann, Thomas A., et al. “Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database.Ann Thorac Surg, vol. 116, no. 5, Nov. 2023, pp. 944–53. Pubmed, doi:10.1016/j.athoracsur.2023.05.025.
Schwann TA, Vekstein AM, Engelman DT, Thibault D, Chikwe J, Engoren M, Gaudino M, Vemulapalli S, Thourani VH, Ailawadi G, Rousou A, Habib RH. Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2023 Nov;116(5):944–953.
Journal cover image

Published In

Ann Thorac Surg

DOI

EISSN

1552-6259

Publication Date

November 2023

Volume

116

Issue

5

Start / End Page

944 / 953

Location

Netherlands

Related Subject Headings

  • Warfarin
  • United States
  • Treatment Outcome
  • Time Factors
  • Thoracic Surgery
  • Societies, Medical
  • Retrospective Studies
  • Respiratory System
  • Postoperative Complications
  • Mitral Valve